TMS Therapy Insurance Denied: How to Fight Back

Transcranial Magnetic Stimulation (TMS) is an FDA-cleared, non-invasive brain stimulation treatment for major depressive disorder that has changed the landscape of treatment-resistant depression care. Despite broad FDA clearance since 2008, TMS claims are frequently denied due to inadequate documentation of failed prior treatments or step therapy requirements. Here is how to appeal successfully.

What Is TMS Therapy?

TMS uses focused magnetic pulses to stimulate specific regions of the brain—most commonly the left dorsolateral prefrontal cortex—to modulate neural activity associated with depression. Unlike ECT, TMS requires no anesthesia, causes no memory loss, and is performed in an outpatient office setting in sessions of 20–40 minutes.

A standard TMS course consists of 30–36 sessions delivered 5 days a week over 6–7 weeks. Newer accelerated protocols (like Stanford's SAINT protocol) deliver multiple sessions per day over fewer days. TMS is FDA-cleared for:

• Major depressive disorder (treatment-resistant)
• Obsessive-compulsive disorder (OCD)
• Anxious depression (with the BrainsWay Deep TMS system)
• Smoking cessation

Why TMS Claims Are Denied

Step Therapy — Insufficient Failed Antidepressant Trials

The single most common denial reason: the insurer requires proof that the patient has failed an adequate number of antidepressant trials before approving TMS. Most insurers require failure of 2–4 antidepressants from different pharmacological classes, at adequate doses, for at least 4–6 weeks each. If documentation of prior treatment is incomplete, the claim is denied—regardless of clinical appropriateness.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior Authorization Requirements

TMS requires prior authorization from virtually every commercial insurer and Medicare Advantage plan. Denial at the prior auth stage—before treatment begins—is the norm when documentation packages are incomplete.

Session Count Limits

Most insurers limit TMS coverage to one course of treatment per depressive episode (typically 30–36 sessions). Additional courses, retreatment after relapse, or maintenance TMS sessions are frequently denied.

OCD and Other Indications

For FDA-cleared non-depression indications like OCD, coverage policies lag behind FDA clearance. Some insurers still deny TMS for OCD as not covered under their specific policy, even though FDA clearance provides a strong medical necessity argument.

Accelerated TMS Protocols

Newer accelerated TMS protocols (multiple sessions per day) are frequently denied as experimental, even when backed by strong clinical evidence from Stanford and other major research centers.

How to Appeal a TMS Denial

Build a Comprehensive Antidepressant Treatment History

The foundation of a successful TMS appeal is meticulous documentation of prior treatment failures. For each antidepressant trial, document:

• Drug name and pharmacological class (SSRI, SNRI, TCA, MAOI, atypical)
• Starting and maximum dose achieved
• Duration of trial at therapeutic dose (minimum 4 weeks at full dose)
• Reason for discontinuation: inadequate response or intolerable side effects
• Any augmentation strategies attempted (lithium, atypical antipsychotics, thyroid hormone)

Use the MGH ATRQ (Antidepressant Treatment Response Questionnaire) or ATHF format to organize this history. Many denials are reversed simply by submitting organized documentation that was missing from the original request.

Cite the APA Practice Guideline

The American Psychiatric Association's Practice Guideline for Major Depressive Disorder explicitly endorses TMS as an evidence-based treatment for TRD. Quote directly: "TMS is recommended for patients with MDD who have not responded adequately to antidepressant medication." This guideline is the clinical standard insurers are supposed to apply.

Address "Experimental" Objections With FDA Clearance

If the denial claims TMS is experimental, cite the FDA 510(k) clearance dates: 2008 (MDD, NeuroStar), 2013 (MDD, BrainsWay Deep TMS), 2018 (OCD), 2021 (anxious depression). FDA clearance is the regulatory standard for clinical efficacy and safety. An insurer cannot reasonably label an FDA-cleared device "experimental" without contradicting federal regulatory standards.

Appeal Session Limit Denials With Relapse Documentation

For retreatment denials after relapse, document: the clinical course after the initial TMS course (duration of remission), the nature of the relapse (severity, PHQ-9 scores, functional impact), and your psychiatrist's clinical rationale for why retreatment is appropriate. Prior response to TMS is itself a strong predictor of response to retreatment.

Request a Peer-to-Peer With a Psychiatrist

TMS denial peer-to-peer reviews are most effective when conducted by a board-certified psychiatrist who specializes in TMS. Ask whether your TMS provider's medical director can participate.

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word.

Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• What Is Step Therapy?